<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4352611</PMID><DateCompleted><Year>1973</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0042-9686</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>2</Issue><PubDate><Year>1973</Year></PubDate></JournalIssue><Title>Bulletin of the World Health Organization</Title><ISOAbbreviation>Bull World Health Organ</ISOAbbreviation></Journal><ArticleTitle>Poliomyelitis vaccination of infants: preimmunization status and seroconversion.</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>198</EndPage><MedlinePgn>195-8</MedlinePgn></Pagination><Abstract><AbstractText>A study was carried out in Delhi on the preimmunization status of infants aged 2-6 months with regard to poliomyelitis and on seroconversion after the administration of oral poliomyelitis vaccine. It was found that 30.3% of the 204 infants included in the study excreted enteroviruses, 58% of which were found to be polioviruses. Of 197 sera examined for neutralizing antibodies against different types of poliovirus, 73% were found to be triple negative and only 4.0% triple positive. Three doses of oral poliomyelitis vaccine were administered at intervals of 1 month. It was found that 71.8% of the vaccinated infants excreted cytopathogenic agents in the 7 days following the first dose; 80.4% of these agents were found to be polioviruses. Seroconversion was studied in 71 infants, and good antibody responses to all three types of poliovirus were observed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choudhury</LastName><ForeName>D S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Nossik</LastName><ForeName>N N</ForeName><Initials>NN</Initials></Author><Author ValidYN="Y"><LastName>Bindu</LastName></Author><Author ValidYN="Y"><LastName>Vijayan</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Raghavan</LastName><ForeName>N G</ForeName><Initials>NG</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>S S</ForeName><Initials>SS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Bull World Health Organ</MedlineTA><NlmUniqueID>7507052</NlmUniqueID><ISSNLinking>0042-9686</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1973</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1973</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1973</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1973</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4352611</ArticleId><ArticleId IdType="pmc">PMC2481014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Indian Med Assoc. 1964 May 1;42:428-30</Citation><ArticleIdList><ArticleId IdType="pubmed">14158030</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>